Therapies / Pharmaceutical / Pharmaceuticals / Drugs / Therapeutics / Medicine / Drug / RNA / Gene / Genes / RNAi / Gene Therapy / Boston blog main / Boston top stories / Boulder / Denver blog main / Denver top stories / Detroit blog main / Detroit top stories / Indiana blog main / Indiana top stories / National / National blog main / National top stories / New York blog main / New York top stories / Raleigh-Durham blog main / Raleigh-Durham top stories / San Diego blog main / San Diego top stories / San Francisco blog main / San Francisco top stories / Seattle blog main / Seattle top stories / Texas blog main / Texas top stories / Wisconsin blog main / Wisconsin top stories / Alnylam Pharmaceuticals / Ambys Medicines / Amicus Therapeutics / Ampio Pharmaceuticals / Angelman Syndrome / Athenex / BioMarin Pharmaceutical / BlueBird Bio / Centers for Medicare & Medicaid Services / Chris Collins / clinical trials / Competitive Generic Therapy / Cystic Fibrosis / deals / FDA / Gout / hemophilia / Innate Immunotherapeutics / Ironwood Pharmaceuticals / Kyowa Hakko Kirin / Lacerta Therapeutics / lesinurad / Life Sciences / Medicare Advantage / Millendo Therapeutics / Orkambi / OvaScience / Ovid Therapeutics / Pain Therapeutics / Phrma / Protagonist Therapeutics / Regeneron Pharmaceuticals / RegenxBio / RNA Interference / Roundups / Samumed / Sangamo Therapeutics / Sarepta Therapeutics / Spark Therapeutics / SQZ Biotechnologies / Vertex Pharmaceuticals

Bio Roundup: Medicare Drug Prices, FDA Moves, Gene Therapy News & More

Posted on: Aug 10, 2018   |   Posted by: Biotech Mag

Bio Roundup: Medicare Drug Prices, FDA Moves, Gene Therapy News & More

Two imminent FDA rulings on two separate drugs aren't just noteworthy for the patients they'll help, but the long and winding road their developers have taken to get to this...

Continue reading ...



Other Posts from Biotech Mag